KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Common Equity: 2010-2024

Historic Common Equity for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $1.0 billion.

  • Supernus Pharmaceuticals' Common Equity rose 4.22% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 4.22%. This contributed to the annual value of $1.0 billion for FY2024, which is 12.39% up from last year.
  • According to the latest figures from FY2024, Supernus Pharmaceuticals' Common Equity is $1.0 billion, which was up 12.39% from $921.5 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Common Equity peaked at $1.0 billion during FY2024, and registered a low of $744.9 million during FY2020.
  • Its 3-year average for Common Equity is $947.8 million, with a median of $921.5 million in 2023.
  • Data for Supernus Pharmaceuticals' Common Equity shows a peak YoY grew of 25.10% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Common Equity stood at $744.9 million in 2020, then grew by 9.53% to $815.9 million in 2021, then rose by 8.62% to $886.2 million in 2022, then grew by 3.98% to $921.5 million in 2023, then grew by 12.39% to $1.0 billion in 2024.